Two experts address the impact of disease course on therapy, general instructions for patients, individualizing treatment, thymectomy, newer selective immunotherapies and more.
What Are the Treatment Options for Myasthenia Gravis if First-Line Agents Fail?
For the 5% to 20% of patients with generalized myasthenia gravis who have suboptimal response to pyridostigmine or substantial adverse effects, it may be time to consider immunosuppressive therapy. This short review offers guidance on choice of agents.